Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Desvenlafaxine Succinate Sustained Release Administered Orally to Healthy Chinese Subjects.
Phase of Trial: Phase I
Latest Information Update: 28 Jan 2013
At a glance
- Drugs Desvenlafaxine (Primary)
- Indications Depressive disorders; Vasomotor symptoms
- Focus Adverse reactions
- Sponsors Wyeth
- 11 Jul 2009 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 16 Jan 2009 New trial record.